Supplementary figure reveals GPX4 knockdown impact on antioxidant enzyme activity in colorectal cancer cells, highlighting new treatment prospects.
Supplementary Figure S2 validates GPX4 knockdown efficacy, details antioxidant enzyme activities under RSL3 and auranofin treatments, and includes kinetic assays for thioredoxin reductase activity in CRC cells.
No takes yet. Share an insight, caveat, or question.
DeAngelo et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: